Harvard Biosci Stock Price, News & Analysis

Harvard Bioscience (Nasdaq: HBIO) reported Q3 2022 revenues of $26.9 million, a 9% decline year-over-year, driven by a 17% drop in pre-clinical product sales. Gross margin fell due to lower revenues and increased labor/material costs. The company anticipates Q4 revenues to reach approximately $30 million, with improved operating margins between 14%-15%. Key product launches include the Ultrospec 7500 and continuous glucose monitoring devices. Cost optimization efforts are expected to yield $4 million in annual gross margin improvements.

Harvard Bioscience (Nasdaq: HBIO) will release its third-quarter financial results for 2022, covering the period ending September 30, after market close on November 8, 2022. A conference call to discuss the results will take place at 4:30 p.m. ET the same day. Interested participants can register online for dial-in information and a unique PIN number. The earnings release and presentation materials will be accessible on the company's Investor Relations website.

Harvard Bioscience (Nasdaq: HBIO) reported Q2 2022 revenues of $29.2 million, flat year-over-year, with growth in cellular/molecular product revenues offset by declines in pre-clinical revenues and adverse currency effects. Adjusted operating income decreased to $3.1 million due to higher R&D and marketing costs. GAAP operating income rose to $4.0 million thanks to a $4.9 million litigation settlement. Looking ahead, the company anticipates 1-5% revenue growth for the year and plans to reduce its workforce by 5% as part of a strategic optimization.

Harvard Bioscience (Nasdaq: HBIO) is set to announce its Q2 financial results for the period ending June 30, 2022, before the market opens on August 4, 2022. A conference call will follow at 8:00 AM ET for discussions on the financial results.

Participants interested in joining the call can register here.

Harvard Bioscience reported a 7% year-over-year revenue increase for Q1 2022, reaching $28.8 million, despite COVID-19 lockdowns in China affecting operations. Strong North American sales and demand for pre-clinical and cellular/molecular products were key drivers. However, the company faced an operating loss of $6.7 million, influenced by higher material costs and a $5 million legal accrual. Adjusted operating income fell to $2.4 million, with adjusted margins down to 8.2%. Looking ahead, the company expects annual revenue growth of 8% to 13%, alongside improving gross margins.

Harvard Bioscience (Nasdaq: HBIO) has launched SmartStudy™, a new feature for its Buxco® Inhalation System, enhancing precision and cost-efficiency in small animal research. This technology allows researchers to stop the delivery of test articles to individual subjects once the desired dosage is achieved, minimizing error and optimizing resource use. Demonstrations of SmartStudy™ occurred at the Society of Toxicology meeting and will continue at the American Thoracic Society conference. The innovation aims to significantly improve inhalation study methodologies.

Harvard Bioscience, Inc. (Nasdaq: HBIO) is set to announce its financial results for Q1 2022 on May 4, 2022, before market opening. A conference call to discuss these results will take place at 8:00 a.m. ET. Interested parties can join the call by calling toll-free 1 (877) 303-7611 or international 1 (970) 315-0445, using conference ID #6757353. The call will also be available via webcast on the company’s investor relations website.

Harvard Bioscience develops technologies for research and drug development, serving a wide range of clients globally.

Harvard Bioscience reported a 7% revenue increase year-over-year in Q4 2021, totaling $33.1 million, despite global supply chain challenges. Gross margin improved to 59%, fueled by a stronger product mix. Pre-clinical product revenue rose by 18% for the full year, while CMT products grew by 9% in Q4. However, operating income dipped to $1.7 million due to rising material and labor costs. The company anticipates 10-13% revenue growth for 2022, with plans for increased investment in sales and R&D.

Harvard Bioscience (Nasdaq: HBIO) is set to announce its fourth-quarter financial results for the period ending December 31, 2021, on March 8, 2022, prior to market opening. The company will hold a conference call at 8:00 a.m. Eastern Time to discuss these results. Investors can participate by dialing the provided numbers or via the live webcast accessible through their website. Harvard Bioscience specializes in developing technologies for fundamental research and drug development, serving various sectors from academia to pharmaceuticals.